Name (Synonyms) | Correlation | |
---|---|---|
drug384 | Blood samples (collection of 5 mL of blood in a dry tube) Wiki | 1.00 |
There is one clinical trial.
This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time. After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data. The blood samples will be taken at 3 times: T0 (day of inclusion), between 6 weeks and 3 months and 6 months' post-inclusion. Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples. A questionnaire will be completed by the inclusion volunteer (T0) in the study then 1, between 6 weeks and 3 months and 6 months' post-inclusion. The nasopharyngeal swabs will be performed at 2 times: between 6 weeks and 3 months and 6 months post-inclusion for Institut Curie staff who have had at least one of the following three criteria on the sample or questionnaire carried out at T0: - have had RT-PCR+ - and/or presence of antibodies at the 95% threshold - and/or anosmia/ageusia - and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the three criteria above, a nasopharyngeal swab will be performed during the following visits. The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses. If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months and 6 months after inclusion. The nasopharyngeal swabs will be performed at 3 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, and 6 months post-inclusion
Description: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at inclusion Time: 1 dayDescription: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at 1 month Time: 1 monthDescription: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at 3 months Time: 3 monthsDescription: Detection of antibodies against the SARS-CoV-2 virus with serological tests
Measure: Antibodies against the SARS-CoV-2 virus in serum at 6 months Time: 6 monthsDescription: Comparative performance of anti-SARS-CoV-2 antibody detection techniques (sensitivity and specificity of serological tests)
Measure: Comparative performance of anti-SARS-CoV-2 antibody detection techniques Time: 9 monthsDescription: Prevalence of immune subjects for SARS-CoV-2 in a well-defined active healthy population, working at the hospital or not, leading to variable exposure levels
Measure: Prevalence of immune subjects for SARS-CoV-2 Time: 3 monthsDescription: Nature and quantity of anti-SARS-CoV-2 antibodies: ImmunoglobulinM, ImmunoglobulinG and ImmunoglobulinA)
Measure: Nature and quantity of anti-SARS-CoV-2 antibodies Time: 3 monthsDescription: The analysis of the evolution of serology results over time will be done by a mixed model taking into account the repeated framework of the data of a subject
Measure: Evolution of the different antibodies against the SARS-CoV-2 virus over time. Time: 6 monthsDescription: Prevalence of Anti-covid IgA in volonteers RT/PCR+ and/or presence of antibodies at the 95 % threshold and/or COVID symptoms
Measure: Prevalence of Anti-covid IgA response in the nasal mucosa Time: 6 months